trending Market Intelligence /marketintelligence/en/news-insights/trending/AbrHaoAp3_0vxiuE1GMB2Q2 content esgSubNav
In This List

Hancock Jaffe completes $2.7M common stock placement

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Hancock Jaffe completes $2.7M common stock placement

Hancock Jaffe Laboratories Inc. completed its private placement of 2,360,051 common shares to investors for gross proceeds of about $2.7 million.

The Irvine, Calif.-based medical device company plans to use the proceeds to develop its two lead products, VenoValve and CoreoGraft, and to fund working capital and general corporate purposes.

VenoValve is used for treating chronic venous insufficiency — a debilitating condition under which veins in a patient's legs are not working effectively. CoreoGraft is used during heart surgeries.